linjc16/ctgov huggingface dataset:
Realistic Models of Gastrointestinal Bioelectromagnetism

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to look at the electrical activity present in healthy and diseased smooth muscle of the intestines; and develop both mathematical and computer models.

Detailed Description
-----------------
The Superconducting QUantum Interference Device (SQUID)is a large cylinder machine located in a large shielded room that measures magnetic activity of the intestines. Subjects will be asked to lie underneath and get recordings of the electrical activity of their intestines. They will also be asked to have a CT scan done. From these two procedures, the mathematical and computer models will be developed to determine the difference between normal bowels and those that do not have adequate blood supply.

Official Title
-----------------
Realistic Models of Gastrointestinal Bioelectromagnetism

Conditions
-----------------
Ischemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal subjects and those with diseased bowel Exclusion Criteria: Subjects with claustrophobia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Good blood flow<br>Group without ischemia to the small intestine | |
| Poor blood flow<br>Groups that have partial ischemia to their small intestine | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To observe a difference in the electrical activity between normal and diseased smooth muscle of the intestines. |  | 2011 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To create both mathematical and computer models of the electrical activity of the intestines. |  | 2011 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood supply, Mesentery
Therapeutic Processes and Treatment Outcome in Adolescents With Anxiety Disorders

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the relationship between different aspects of cognitive behavior therapy (CBT) and treatment outcome.

Detailed Description
-----------------
Anxiety disorders are common among children; if untreated, they can negatively affect children's lives. Evidence suggests that CBT can benefit children with anxiety disorders, but the causal mechanisms between therapy and beneficial outcomes have not been thoroughly investigated. Audio and videotaped sessions of children currently receiving CBT and those who received CBT in previous trials will be examined. Various rating scales will be used to rate therapeutic alliance, child involvement, and therapist flexibility for each session of CBT. To evaluate potential process variables that contribute to participant drop-out, this study will compare the early process variables for children who complete treatment and for those who discontinue treatment.

Official Title
-----------------
Process as a Predictor of Outcomes in CBT for Youth

Conditions
-----------------
Anxiety Disorders

Intervention / Treatment
-----------------
* Behavioral: Cognitive Behavioral Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Diagnosis of separation anxiety disorder, generalized anxiety disorder, or social phobia At least one English-speaking parent Exclusion criteria: IQ < 80 Psychotic symptoms

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Cognitive Behavioral Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adolescent
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

Study Overview
=================
Brief Summary
-----------------
This is a single-center, open label, non randomized, compassionate use protocol in patients with advanced solid tumor malignancies who were previously enrolled in the phase I study (NCT00878189) of this agent.

Detailed Description
-----------------
This is an expanded access-physician sponsored trial of PF-03084014, a novel gamma-secretase inhibitor being developed for cancer therapy. This trial is designed for patients who have been on a previous Industry-sponsored phase I trial using PF-03084014 for> 1 year. The study is designed to evaluate the safety of prolonged oral administration of single agent PF-03084014. There are two study subjects with desmoid tumor who have been on the trial for a prolonged period of time (54 and 77 months, respectively) with either stable disease or response, indicating significant clinical benefit for a patient population in which there are few options. The goal of this protocol is to allow these subjects, who are clearly benefiting from PF-03084014, to continue to receive it

Official Title
-----------------
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies: Continuing Study Drug Administration in Desmoid Patients Receiving Clinical Benefit

Conditions
-----------------
Neoplasm, Desmoid Tumor

Intervention / Treatment
-----------------
* Drug: PF-03084014


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients who are currently enrolled in A8641014 for > 1 year are eligible Exclusion Criteria: Prior treatment with a gamma secretase inhibitor for treatment of cancer Patients taking Tamoxifen Patients with active graft versus host disease Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness Patients who are pregnant or breast-feeding Patients with clinical evidence of central nervous system disease

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 101 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Refractory Tumors, Advanced Solid Tumors
Network Analysis of Adult MDD and ADHD

Study Overview
=================
Brief Summary
-----------------
The study is an investigation to determine co-morbid symptoms between adult major depressive disorder (MDD) and adult attention-deficit hyperactivity disorder (ADHD) using a novel statistical technique called network analysis.

Official Title
-----------------
Network Analysis of Co-morbid Symptoms of Adult Major Depressive Disorder and Attention-deficit Hyperactivity Disorder in an Outpatient Population

Conditions
-----------------
ADHD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participants have a diagnosis of MDD or ADHD or both participants are competent to consent to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Co-morbidity | Characterize the ADHD/MDD symptom network in a psychiatric outpatient setting comprised of adults | September 8, 2021 | 
| Network reliability | Determine the stability and reliability of this network | September 8, 2021 | 
| Central symptoms | Determine the central symptoms that lead to co-activation of ADHD/MDD clusters | September 8, 2021 |
NOCTURNAL PAIN After Knee Arthroplasty : Incidence and Risk Factor: an Observational Study

Study Overview
=================
Brief Summary
-----------------
In prosthetic knee surgery, there is a certain number of patients with post-operative nocturnal pain. The purpose of our study is to determine the impact of this problem and to better understand its risk factors.

Detailed Description
-----------------
In prosthetic knee surgery, there is a certain number of patients with post-operative nocturnal pain. The purpose of our study is to determine the impact of this problem and to better understand its risk factors. This is a poorly studied issue and the study could better detect, evaluate and treat painful patients after knee replacement surgery.

Official Title
-----------------
NOCTURNAL PAIN After Knee Arthroplasty : Incidence and Risk Factor: an Observational Study

Conditions
-----------------
Knee Osteoarthritis, Pain, Postoperative, Prosthesis (Internal) Complications, Nocturnal Frequency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing elective primary Total knee arthroplasty or unicompartmental knee arthroplasty due to knee joint osteoarthritis Older than 18 years Willing and able to complete pre and postoperative surveys Exclusion Criteria: History of drug abuse Previous knee arthroplasty Mental disorders Rheumatoid arthritis Chronic renal disease Chronic hematological diseases (sickle cell disease, haemochromatosis...)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| nocturnal pain | response to question (yes-no) Does the pain in the operated knee wake you up at night or prevent you from sleeping? | from day 1 of surgery until 1 year post surgery |
Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis

Study Overview
=================
Brief Summary
-----------------
This is a randonmized, masked, placebo-controlled parallel group, clinical trial to evaluate the effects of three different doses of N-acetyl L-cysteine (NAC) and placebo on patient safety and on physical and transport properties of expectorated sputum. Patient sumptoms, quality of life and exacerbation will also be followed as well as pulmonary function testing and functional exercise capacity. We hypothesized that a prolongeed course of oral NAC favorably affects the morbidity of chronic bronchitis, particularly the incidence of acute exacerbations.

Official Title
-----------------
A Phase II Multicenter Efficacy, Safety and Dose-Effect Study of the Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable, Chronic Bronchitis

Conditions
-----------------
Chronic Bronchitis

Intervention / Treatment
-----------------
* Drug: Oral N-acetycystein (NAC)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Smokers (past or current,20 pack years) with diagnosis of chronic bronchitis expectorate sputum daily FEV1 of 40-70% understand and fill out questionnaire daily Exclusion Criteria: other investigational within 30 days change in smoking habit within 6 months pulmonary diagnosis other that chronic bronchitis significant renal, cardiac, hepatic or endocrine diseases psychiatric disorder or evidence of alcoholism or drug abuse within year

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Oral N-acetycystein (NAC)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute exacerbations |  |  | 
| Clinical assessments |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional exercise capacity |  |  | 
| Relationship between mucus physical and transport properties |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Bronchitis, N-acetylcysteine (NAC), Quality of Life, Mucus
Prevalence of Sarcopenia and Undernutrition in Patients With Cirrhosis and Abdominal Hernia

Study Overview
=================
Brief Summary
-----------------
The study evaluates whether sarcopenia influences the prevalence of abdominal hernias in patients with cirrhosis.

Detailed Description
-----------------
Sarcopenia is a common condition in patients with cirrhosis, with a prevalence of around 50%. It is unknown if the presence of sarcopenia may influence the prevalence of abdominal hernias in this group of patients. Clinical, nutritional and radiological evaluation will be performed in two groups of cirrhotic patients to evaluate this hypothesis.

Official Title
-----------------
Prevalence of Sarcopenia and Undernutrition in Patients With Cirrhosis and Abdominal Hernia

Conditions
-----------------
Cirrhosis, Sarcopenia, Malnutrition, Hernia, Abdominal

Intervention / Treatment
-----------------
* Diagnostic Test: Computed Tomography Scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 18 years Previous diagnosis of cirrhosis Exclusion Criteria: Acutely decompensated cirrhosis Other chronic diseases in advanced stage (e.g. cardiac failure, chronic obstructive pulmonary disease, cancer) Cognitive impairment, delirium, non-controlled psychosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>This group consists of cirrhotic patients with any abdominal hernia | Diagnostic Test: Computed Tomography Scan<br>* The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.<br>* Other names: Royal Free Hospital-Global Assessment;|
| Group 2<br>This group consists of cirrhotic patients without any hernias | Diagnostic Test: Computed Tomography Scan<br>* The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.<br>* Other names: Royal Free Hospital-Global Assessment;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Sarcopenia | Prevalence of Sarcopenia in patients with cirrhosis | Through study completion (an average of 1 year) | 
| Influence of Sarcopenia in Prevalence of Abdominal Hernias in Patients with Cirrhosis | Influence of Sarcopenia in Prevalence of Abdominal Hernias in Patients with Cirrhosis | Through study completion (an average of 1 year) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cirrhosis, Sarcopenia, Malnutrition, Inguinal hernia, Umbilical hernia, Undernutrition
Awareness of Operating Room Staff About WHO OR Checklist

Study Overview
=================
Brief Summary
-----------------
to understand and analyze awareness of proper timing of when to sing in, time out, and sign out for patients who will be operated in Hail multidisciplinary centers, Saudi Arabia. its role in improving communication in OR, and preventing errors. how frequent not comply and potentials of non compliance. how frequent dose WHO OR check list will cause anxiety in the staff, psychological insult ,potentials to be replaced or adjusted according to each specialty needs.

Official Title
-----------------
Awareness of Operating Room Staff About WHO OR Checklist

Conditions
-----------------
Safety Issues

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: operating room staff of hail region hospitals - Exclusion Criteria: none -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| predictive power of respondent on awareness of WHO OR checklist | will include demographics include: gender, specialty, hospital name ,utilization of WHO OR checklist habits, commitment of staff ,communication improvement, its psychological impact over staff, significance potentials, possibility of adjustment. | 20 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
WHO checklist, WHO OR ckecklist
Premedication Simethione Improves Visibility During Bowel Cleansing for Colonoscopy

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy, visibility of low volume polyethyleneglycol-simeticone (2-LPEG-S) for colonoscopy.

Detailed Description
-----------------
In this randomized controlled study, consecutive outpatients scheduled for elective colonoscopy were randomized into two groups. Group A patients (n = 300) used only 2 L PEG before colonoscopy. Patients in group B (n = 300) were additionally advised to simeticone plus 2 L PEG, The overall quality of colonoscopy cleaning was evaluated using the Boston Bowel Preparation Scale by a single endoscopist who was blinded to the intervention. Visibility was blindly assessed for the amount of air bubbles and adenoma detection rate (ADR). Difficulty of procedure, and adverse events were also evaluated.

Conditions
-----------------
Bowel Preparation Scale, the Amount of Air Bubble, Adenoma Detection Rate

Intervention / Treatment
-----------------
* Drug: 2L PEG
* Drug: 2L PEG+simethicone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients are between 18-65 years old undergoing colonoscopy for diagnostic investigation, colorectal cancer screening or follow-up Exclusion Criteria: suspected gastrointestinal obstruction or perforation severe acute inflammatory bowel disease toxic megacolon ileus or gastric retention, ileostomy, hypersensitivity to any of the ingredients pregnancy and lactation and/or at a risk of becoming pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 2L PEG<br>only used 2L PEG | Drug: 2L PEG<br> <br> |
| Experimental: Simethione+2L PEG<br>used 2L PEG+Simethione | Drug: 2L PEG+simethicone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adenoma detection rate |  | 2 days | 
| bowel preparation scale |  | 2 days | 
| the amount of air bubbles | Five areas of the colon (rectosigmoid, descending, transverse, ascending, and cecum) were graded for the amount of air bubbles.The amount of intraluminal air bubbles was classified into four grades as shown below: Grade 0 = No or minimal scattered bubbles; Grade 1 = Bubbles covering at least half the luminal diameter; Grade 2 = Bubbles covering the circumference of the lumen; Grade 3 = Bubbles filling the entire lumen. | 2 days |
Predictive Clinical and Biological Parameters in Breast Cancer

Study Overview
=================
Brief Summary
-----------------
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation

Official Title
-----------------
Research of Predictive Clinical and Biological Parameters in Breast Cancer

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Genetic: molecular alteration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: breast cancer age > 18 signed informed consent Exclusion Criteria: emergency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: breast cancer<br>blood and tumor sample | Genetic: molecular alteration<br>* research of molecular alteration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| molecular alteration in breast cancer | gene expression level | average of 4 weeks after diagnosis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| relation between molecular alteration and clinical and histological characteristics | hazard ratio between molecular alteration and clinical and histological characteristics | up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer